| 000 | 00965nam a22002657a 4500 | ||
|---|---|---|---|
| 001 | D0001C000140 | ||
| 003 | DOH | ||
| 005 | 20210204135757.0 | ||
| 008 | 210204b ||||| |||| 00| 0 eng d | ||
| 245 | 0 | 0 |
_aCombining antivirals and immunomodulators to fight COVID-19 / _cVincent Feuillet [ansd two others] |
| 580 | _aIn: Trends Immunol . 2021 Jan; 42 (1) pages:31-44. doi: 10.1016/j.it.2020.11.003 | ||
| 650 | 2 |
_aAngiotensin-Converting Enzyme 2 _x immunology |
|
| 650 | 2 |
_aAngiotensin-Converting Enzyme 2 _xmetabolism |
|
| 650 | 2 |
_aAntiviral Agents _xtherapeutic use |
|
| 650 | 2 |
_aCOVID-19 _xdrug therapy |
|
| 650 | 2 |
_aCOVID-19 _xvirology |
|
| 650 | 2 |
_ammunologic Factors _x immunology |
|
| 650 | 2 |
_aImmunologic Factors _xmetabolism |
|
| 650 | 2 |
_aSARS-CoV-2 _xdrug effects |
|
| 700 | 1 | _aFeuillet, Vincent | |
| 700 | 1 | _aCanard, Bruno | |
| 700 | 1 | _aTrautmann, Alain | |
| 856 | _uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664349/ | ||
| 942 | _cCV | ||
| 999 |
_c2669 _d2669 |
||